The Institute of Clinical and Economic Review (ICER) on Wednesday announced the creation of a new advisory group to play a key role in a new report focused on unsupported drug price increases.
ICER says it plans to issue its report during the first quarter of 2019.
“The federal government has expressed concern about drug price increases, and several states have already passed laws that will generate lists of drugs with substantial price increases so that policy makers and the public can seek greater transparency,” ICER President Steven Pearson said in a statement. “What isn’t available to federal or state policymakers, to patients, or to other stakeholders is an explicit and independent approach to determining whether price increases are supported by new clinical evidence or other factors. That’s the goal for this new initiative.”
The multi-stakeholder advisory committee will include:
- Dan Danielson, Premera Blue Cross pharmacy manager;
- Kaha Hizanishvili, MassHealth director of strategy and pharmacy purchasing; and
- Jane Horvath, National Academy for State Health Policy senior policy fellow.
To read more about the advisory group, read the full press release here.